Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
330
datasets available to search
ShareScore release 0.9.0
Dataset results
330 results for “hydroxychloroquine”
Molecular docking: Hydroxychloroquine alternative to inhibit the COVID-19 main protease (MPro)
<p>Docking study shows best binding affinity against the main protease of COVID-19. As per the docking results top twelve compounds as a MPro inhibitor, Coumermycin A1 (-10.2), Irinotecan (-9.4), Suramin (-9.4), Trovafloxacin (-9.3), Aclarubicin (-9.0), Dactinomycin (-9.0), TG-100801 (-9.0), Raltegravir (-8.9), Digoxin (-8.9), Etoposide (-8.9), Doxorubicin (-8.8), and Venetoclax (-8.8) from the tested compounds.</p> <p>ARULANANDAM, CHARLI DEEPAK (2020): Molecular docking: Hydroxychloroquine alternative to inhibit the COVID-19 main protease (MPro). figshare. Dataset. https://doi.org/10.6084/m9.figshare.12032745.v26</p>
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
ClinicalTrials.gov study NCT04329832. IPD Sharing: NO. Countries: 1. Publications: 3.
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
ClinicalTrials.gov study NCT04334148. IPD Sharing: YES. Countries: 1. Publications: 1.
Data from Mehra et al. (2020-05-29), "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis"
<p>Recent <a href="http://doi.org/dw8t">reports</a> have identified errors and implausible results in the <a href="http://doi.org/ggwzsb">title paper</a>, few of which have been corrected to date. To facilitate analysis, I provide a spreadsheet containing all data from tables in the corrected version (2020-05-29), from both the main text (html) and supporting information (PDF).</p> <p><br> The data is uploaded to this publicly-funded repository with the <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255293/">permission</a> of the copyright holder: <em>"Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories ... with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source."</em> Text and data mining are also <a href="http://web.archive.org/web/20200602210529/https://www.elsevier.com/connect/coronavirus-information-center">permitted</a>: <em>"These articles are also available to download with rights for full text and data mining, re-use and analyses for as long as needed."</em></p>
Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials
<p><strong>Background</strong>: To summarize specific adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir in patients with COVID-19.</p> <p><strong>Methods</strong>: We searched 32 databases through 27 October 2020. We included randomized trials comparing any of the drugs of interest to placebo or standard care, or against each other. We conducted fixed-effects pairwise meta-analysis and assessed the certainty of evidence using the GRADE approach.</p> <p><strong>Results</strong>: We included 16 randomized trials which enrolled 8226 patients. For most interventions and outcomes the certainty of the evidence was very low to low except for gastrointestinal adverse effects from hydroxychloroquine, which was moderate certainty. Compared to standard care or placebo, low certainty evidence suggests that remdesivir may not have an important effect on acute kidney injury or cognitive dysfunction/delirium. Low certainty evidence suggests that hydroxychloroquine may increase the risk of cardiac toxicity (and cognitive dysfunction/delirium, whereas moderate certainty evidence suggests hydroxychloroquine probably increases the risk of diarrhoea (RD 106 more per 1000, 95% CI: 48 more to 175 more) and nausea and/or vomiting (RD 62 more per 1000, 95% CI: 23 more to 110 more) compared to standard care or placebo. Low certainty evidence suggests lopinavir/ritonavir may increase the risk of diarrhoea and nausea and/or vomiting compared to standard care or placebo.</p> <p><strong>Discussion</strong>: Hydroxychloroquine probably increases the risk of diarrhoea and nausea and/or vomiting and may increase the risk of cardiac toxicity and cognitive dysfunction/delirium. Lopinavir/ritonavir may increase the risk of diarrhoea and nausea and/or vomiting. Remdesivir may have no important effect on risk of acute kidney injury or cognitive dysfunction/delirium. These findings provide important information to support the development of evidence-based management strategies for patients with COVID-19.</p> <p><strong>Funding</strong>: This study was supported by the Canadian Institutes of Health Research (grant: VR4-172738)</p> <p><strong>Registration</strong>: Not registered in PROSPERO, protocol available in the supplementary material of BMJ 2020;370:m2980; http://dx.doi.org/10.1136/bmj.m2980.</p>
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
ClinicalTrials.gov study NCT04332991. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04735068. IPD Sharing: Not stated. Countries: 1. Publications: 1.
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
ClinicalTrials.gov study NCT03032406. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
ClinicalTrials.gov study NCT01978184. IPD Sharing: Not stated. Countries: 1. Publications: 2.
PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine
ClinicalTrials.gov study NCT04353037. IPD Sharing: YES. Countries: 1. Publications: 17.
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
ClinicalTrials.gov study NCT04318444. IPD Sharing: NO. Countries: 1. Publications: 1.
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
ClinicalTrials.gov study NCT01326533. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Will Hydroxychloroquine Impede or Prevent COVID-19
ClinicalTrials.gov study NCT04341441. IPD Sharing: NO. Countries: 1. Publications: 10.
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
ClinicalTrials.gov study NCT04303507. IPD Sharing: YES. Countries: 10. Publications: 4.
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
ClinicalTrials.gov study NCT02316340. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
ClinicalTrials.gov study NCT01128296. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
ClinicalTrials.gov study NCT04491994. IPD Sharing: YES. Countries: 1. Publications: 8.
Trial of Hydroxychloroquine In Covid-19 Kinetics
ClinicalTrials.gov study NCT04353271. IPD Sharing: NO. Countries: 1. Publications: 29.
A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
ClinicalTrials.gov study NCT01842594. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
ClinicalTrials.gov study NCT00486603. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.